phone icon (917) 310-3371 Book haloperidol decanoate evaluation
Nao Medical

Long-acting haloperidol

Haloperidol Decanoate Injection Care in New York

Product-specific evaluation, oral-treatment verification, delivery, administration, and monitoring coordination.

The current haloperidol decanoate label indicates it for schizophrenia in adults who were previously taking a stable dose of immediate-release oral haloperidol. It is administered by deep intramuscular injection every four weeks. Nao starts with a virtual psychiatric evaluation and does not promise a prescription, conversion, or injection before the full plan is verified.

Nao Medical patient consultation
Nao Medical clinical visit
Nao Medical clinic interior
Evaluation comes before treatment A virtual psychiatric evaluation comes first. Product, order, delivery, staff, and site are confirmed separately.

What must be confirmed before depot haloperidol

Conversion is individualized and requires more than a medication name or a prior injection date.

Current indication

The modern label specifies adults with schizophrenia who were previously taking a stable dose of immediate-release oral haloperidol.

Prescriber-selected conversion

The prescriber reviews the stable oral dose, symptoms, response, side effects, age, and interaction risks before selecting the depot regimen.

Four-week schedule

Haloperidol decanoate is administered by deep intramuscular injection every four weeks; dose changes and temporary oral treatment require clinical direction.

Ongoing prescriber responsibility

A psychiatric prescriber remains responsible for symptom control, movement monitoring, cardiac risk, dose changes, and late-dose decisions.

A records-first haloperidol decanoate workflow

The evaluation verifies stability, conversion, safety, and continuity before the administration team confirms a clinic visit.

1. Verify oral stability

Confirm the immediate-release oral haloperidol dose, duration, adherence, response, side effects, and reason for considering a long-acting injection.

2. Review safety

Assess movement symptoms, prior neuroleptic malignant syndrome, QT or rhythm risk, Parkinson's disease or Lewy body dementia, seizures, pregnancy, and interacting medicines.

3. Confirm order and delivery

Review the signed dose and date, outside-prescriber responsibility, benefits, acquisition path, patient-specific medication, and arrival at the eligible site.

4. Administer and follow

Document deep intramuscular administration, monitor immediate concerns, continue psychiatric follow-up, and plan the next four-week dose.

What to prepare for the first evaluation

Complete records reduce avoidable delays and help the clinician separate a new decision from continuation of an established plan.

  • Immediate-release oral haloperidol dose, duration, response, adherence, and adverse-effect history.
  • Prior depot injection records, last dose, next due date, and any temporary oral-treatment plan.
  • Current medicines, allergies, cardiac history, ECG information if available, falls, seizures, and movement symptoms.
  • Signed order, prescriber contact, insurance, pharmacy, and delivery information.

Safety, monitoring, and treatment boundaries

The clinical plan is individualized. These points highlight questions that need explicit review rather than replacing the current label, a full evaluation, or emergency care.

Movement effects

Report new stiffness, tremor, restlessness, slowed movement, spasms, or involuntary facial, tongue, trunk, or limb movements promptly.

Cardiac risk

The prescriber reviews QT prolongation, rhythm history, electrolyte concerns, and medicines that can increase cardiac risk.

Neurologic limits

The current label lists Parkinson's disease and dementia with Lewy bodies among contraindications and warns against dementia-related psychosis use.

Dose changes take planning

Because the medicine is long acting, dose modification and late-dose management require prescriber oversight and may include temporary oral haloperidol.

When to get urgent or emergency help

Call 911 for collapse, a dangerous heart rhythm symptom, a seizure, trouble breathing, high fever with severe stiffness or confusion, or immediate danger.

Virtual evaluation first, administration site confirmed later

Start with virtual psychiatry. The team reviews the medicine, order, dose history, delivery, trained staff, and site before scheduling an in-person injection. Do not arrange a shipment or travel to a clinic until the team confirms the plan.

Choose condition-focused care for diagnosis and long-term treatment planning. Choose a medicine-specific service for initiation, access, monitoring, delivery, or administration questions.

Fluphenazine decanoate

Review another older depot antipsychotic without assuming equivalent conversion or monitoring.

Clinical and regulatory sources

These authoritative sources were checked on August 1, 2026. Drug labels and guidance can change, so the treating clinician uses current information for each decision.

Common questions about Haloperidol decanoate

The current label indicates it for schizophrenia in adults who were previously taking a stable dose of immediate-release oral haloperidol.
The current label describes deep intramuscular administration every four weeks by a healthcare professional.
The current indication and conversion instructions rely on prior stable immediate-release oral haloperidol treatment. The prescriber must verify the oral history before a depot plan.
No. Conversion requires a psychiatric evaluation of the stable oral dose, response, side effects, age, medical risks, interactions, and current symptoms.
Contact the responsible prescriber promptly. The label says an immediate-release oral haloperidol product may be considered during dosage modification when symptoms worsen, but that decision is individualized.
Report stiffness, tremor, restlessness, muscle spasms, slowed movement, or involuntary movements of the face, tongue, trunk, or limbs.
Nao can review the order and records. Acceptance requires a responsible prescriber, clinically complete plan, patient-specific medication delivery, and a confirmed administration site.
Call the responsible prescriber before another dose. The plan depends on the gap, symptoms, prior dose, and whether temporary oral treatment is clinically appropriate.
Book haloperidol decanoate evaluation Call with questions

Updated August 1, 2026. This information does not replace an individual medical evaluation. A licensed clinician determines diagnosis, medication eligibility, prescribing, testing, dosing, administration, and follow-up.

Health information notice

General information only. This page is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.

Content was updated August 1, 2026 from the sources cited on this page. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.